Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 214

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 214
---
 accounted for retrospectively.

The Company adopted ASC
Topic 606, Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC 606 on April 1, 2017 using
the full retrospective method which requires the Company to present the financial statements for all periods as if Topic 606 had
been applied to all prior periods. The Company derives revenue principally from provision of In vitro fertilization (“IVF”)
treatment and surrogacy and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:

| (1) | identify its contracts                                                                                                              
 with customers;                                                                                                                     |
| (2) | identify its performance                                                                                                            
 obligations under those contracts;                                                                                                  |
| (3) | determine the transaction                                                                                                           
 prices of those contracts;                                                                                                          |
| (4) | allocate the transaction                                                                                                            
 prices to its performance obligations in those contracts; and                                                                       |
| (5) | recognize revenue when                                                                                                              
 each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the 
 client in an amount that reflects the consideration expected in exchange for those services.                                        |

The Company enters into
verbal agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify
the scope of services, service fees, and payment terms. Agreements are acknowledged and consent forms are signed by the customers prior
to each promised service or bundle of services are inter dependant. All the contracts have commercial substance, and it is probable that
the Company will collect considerations from its customers for service component as settlement is predominantly required prior to performance
of the promised service.

The Company derives its
revenues from two sources: (1) revenue from IVF treatment, and (2) revenue from surrogacy and ancillary caring services.

Revenue from IVF treatment

In vitro fertilization (“IVF”)
treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized
embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment
as well as procedures and brings benefits to clients as the service of bundles service is completed. Revenue from IVF treatment is recognized
at a point in time when different treatment and/or procedure or bundles thereof, are completed in clinic. The full completion of the
various procedures and treatments are evidenced by treatment cards and reports included within the patient